Rajwanth R. Veluswamy, MD, MSCR, discusses universal KRAS testing, the frontline immunotherapy signal in KRAS G12C+ NSCLC, and next-generation G12C inhibitors.
Rajwanth R. Veluswamy, MD, MSCR
Advertisement
Articles by Rajwanth R. Veluswamy, MD, MSCR
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Tam-Peli Reduces Risk of Death by 54% vs Topotecan in Relapsed SCLC
2
Ris-Rez Extends Median OS to 18.5 Months vs Topotecan in Relapsed SCLC
3
Iza-Bren Elicits 33% ORR, 6.9-Month PFS in Post-Osimertinib EGFR-Mutated NSCLC
4
Early Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC
5